
Chris Langmead, PhD
CEO & Co-Founder
Chris has >25 years experience in pharmacology and psychiatry drug discovery across pharma (SB, GSK), biotech (Heptares Therapeutics), and academia (Monash University), leading multiple CNS programs from inception to clinical development. He is also Professor of Pharmacology and Director of the Neuromedicines Discovery Centre at Monash University.

Greg Stewart, PhD
CSO & Co-Founder
Greg is an experienced neurobiologist and pharmacologist, with over two decades of experience in drug discovery in France (CNRS) and Australia (Monash University, Servier), applying innovative ideas to address the unique challenges of CNS disorders and progress projects into preclinical development. He is also Senior Research Fellow in the Neuromedicines Discovery Centre at Monash University.

Jess Nithianantharajah, PhD
VP, Translational Biology & Co-Founder
Jess has >25 years research experience in behavioural neuroscience, specifically cognitive analyses in rodent models for neurodevelopmental psychiatric conditions, working in Australia (University of Melbourne, The Florey) and the UK (University of Cambridge, University of Edinburgh). She is also Head of Florey Department of Neuroscience and Mental Health at the University of Melbourne and Research Lead for the Mental Health Mission at The Florey.
Advisors
Anissa Abi-Dargham, MD – Chief Medical Advisor
Professor and Chair, Department of Psychiatry and Behavioral Health, Stony Brook University, USA
Bob Atwill, MBA – Strategic Advisor
Principal, Eaton Square, Australia
